Quels sont les facteurs de risque pour des niveaux élevés de GFAP ?
Les traumatismes crâniens, les AVC et certaines maladies neurodégénératives sont des facteurs de risque.
Facteurs de risqueTraumatismes crâniens
#2
L'âge influence-t-il les niveaux de GFAP ?
Oui, l'âge avancé est un facteur de risque pour des niveaux plus élevés de GFAP.
ÂgeFacteurs de risque
#3
Les antécédents familiaux augmentent-ils le risque de GFAP élevée ?
Oui, des antécédents familiaux de maladies neurologiques peuvent augmenter le risque de GFAP élevée.
Antécédents familiauxMaladies neurologiques
#4
Le mode de vie influence-t-il les niveaux de GFAP ?
Oui, un mode de vie sédentaire et une mauvaise alimentation peuvent augmenter les niveaux de GFAP.
Mode de vieAlimentation
#5
Les infections peuvent-elles affecter la GFAP ?
Oui, certaines infections, comme la méningite, peuvent entraîner une augmentation des niveaux de GFAP.
InfectionsMéningite
{
"@context": "https://schema.org",
"@graph": [
{
"@type": "MedicalWebPage",
"name": "Protéine gliofibrillaire acide : Questions médicales les plus fréquentes",
"headline": "Protéine gliofibrillaire acide : Comprendre les symptômes, diagnostics et traitements",
"description": "Guide complet et accessible sur les Protéine gliofibrillaire acide : explications, diagnostics, traitements et prévention. Information médicale validée destinée aux patients.",
"datePublished": "2024-04-23",
"dateModified": "2026-07-12",
"inLanguage": "fr",
"medicalAudience": [
{
"@type": "MedicalAudience",
"name": "Grand public",
"audienceType": "Patient",
"healthCondition": {
"@type": "MedicalCondition",
"name": "Protéine gliofibrillaire acide"
},
"suggestedMinAge": 18,
"suggestedGender": "unisex"
},
{
"@type": "MedicalAudience",
"name": "Médecins",
"audienceType": "Physician",
"geographicArea": {
"@type": "AdministrativeArea",
"name": "France"
}
},
{
"@type": "MedicalAudience",
"name": "Chercheurs",
"audienceType": "Researcher",
"geographicArea": {
"@type": "AdministrativeArea",
"name": "International"
}
}
],
"reviewedBy": {
"@type": "Person",
"name": "Dr Olivier Menir",
"jobTitle": "Expert en Médecine",
"description": "Expert en Médecine, Optimisation des Parcours de Soins et Révision Médicale",
"url": "/static/pages/docteur-olivier-menir.html",
"alumniOf": {
"@type": "EducationalOrganization",
"name": "Université Paris Descartes"
}
},
"isPartOf": {
"@type": "MedicalWebPage",
"name": "Protéines de filaments intermédiaires",
"url": "https://questionsmedicales.fr/mesh/D007381",
"about": {
"@type": "MedicalCondition",
"name": "Protéines de filaments intermédiaires",
"code": {
"@type": "MedicalCode",
"code": "D007381",
"codingSystem": "MeSH"
},
"identifier": {
"@type": "PropertyValue",
"propertyID": "MeSH Tree",
"value": "D12.776.220.475"
}
}
},
"about": {
"@type": "MedicalCondition",
"name": "Protéine gliofibrillaire acide",
"alternateName": "Glial Fibrillary Acidic Protein",
"code": {
"@type": "MedicalCode",
"code": "D005904",
"codingSystem": "MeSH"
}
},
"author": [
{
"@type": "Person",
"name": "Henrik Zetterberg",
"url": "https://questionsmedicales.fr/author/Henrik%20Zetterberg",
"affiliation": {
"@type": "Organization",
"name": "Department of Psychiatry and Neurochemistry, Institute of Neuroscience and Physiology, the Sahlgrenska Academy at the University of Gothenburg, 43141 Mölndal, Sweden."
}
},
{
"@type": "Person",
"name": "Akio Kimura",
"url": "https://questionsmedicales.fr/author/Akio%20Kimura",
"affiliation": {
"@type": "Organization",
"name": "Department of Neurology, Gifu University Graduate School of Medicine."
}
},
{
"@type": "Person",
"name": "Youming Long",
"url": "https://questionsmedicales.fr/author/Youming%20Long",
"affiliation": {
"@type": "Organization",
"name": "Department of Neurology, the Second Affiliated Hospital of Guangzhou Medical University, 250# Changgang East Road, Guangzhou 510260 Guangdong Province, China; Institute of Neuroscience and the Second Affiliated Hospital of Guangzhou Medical University, Key Laboratory of Neurogenetics and Channelopathies of Guangdong Province and the Ministry of Education of China, Collaborative Innovation Center for Neurogenetics and Channelopathies, 250# Changgang East Road, Guangzhou 510260, Guangdong Province, China. Electronic address: youminglong@126.com."
}
},
{
"@type": "Person",
"name": "Markus Otto",
"url": "https://questionsmedicales.fr/author/Markus%20Otto",
"affiliation": {
"@type": "Organization",
"name": "Department of Neurology, Universitätsklinikum Halle (Saale), Halle (Saale), Germany."
}
},
{
"@type": "Person",
"name": "Kaj Blennow",
"url": "https://questionsmedicales.fr/author/Kaj%20Blennow",
"affiliation": {
"@type": "Organization",
"name": "Department of Psychiatry and Neurochemistry, Institute of Neuroscience and Physiology, the Sahlgrenska Academy at the University of Gothenburg, 43141 Mölndal, Sweden."
}
}
],
"citation": [
{
"@type": "ScholarlyArticle",
"name": "Autoimmune encephalitis in glial fibrillary acidic protein astrocytopathy.",
"datePublished": "2024-05-09",
"url": "https://questionsmedicales.fr/article/38724215",
"identifier": {
"@type": "PropertyValue",
"propertyID": "DOI",
"value": "10.1136/bcr-2024-260628"
}
},
{
"@type": "ScholarlyArticle",
"name": "Clinical and biological relevance of glial fibrillary acidic protein in Alzheimer's disease.",
"datePublished": "2023-11-03",
"url": "https://questionsmedicales.fr/article/37924152",
"identifier": {
"@type": "PropertyValue",
"propertyID": "DOI",
"value": "10.1186/s13195-023-01340-4"
}
},
{
"@type": "ScholarlyArticle",
"name": "Serum neurofilament and glial fibrillary acidic protein in idiopathic and seropositive transverse myelitis.",
"datePublished": "2023-09-01",
"url": "https://questionsmedicales.fr/article/37688927",
"identifier": {
"@type": "PropertyValue",
"propertyID": "DOI",
"value": "10.1016/j.msard.2023.104957"
}
},
{
"@type": "ScholarlyArticle",
"name": "Case report: Autoimmune glial fibrillary acidic protein astrocytopathy with overlapping autoimmune syndrome.",
"datePublished": "2024-10-11",
"url": "https://questionsmedicales.fr/article/39464885",
"identifier": {
"@type": "PropertyValue",
"propertyID": "DOI",
"value": "10.3389/fimmu.2024.1485374"
}
},
{
"@type": "ScholarlyArticle",
"name": "Glial Fibrillary Acidic Protein Autoimmunity After Aseptic Meningitis: A Report of 2 Cases.",
"datePublished": "2023-11-10",
"url": "https://questionsmedicales.fr/article/37949666",
"identifier": {
"@type": "PropertyValue",
"propertyID": "DOI",
"value": "10.1212/NXI.0000000000200180"
}
}
],
"breadcrumb": {
"@type": "BreadcrumbList",
"itemListElement": [
{
"@type": "ListItem",
"position": 1,
"name": "questionsmedicales.fr",
"item": "https://questionsmedicales.fr"
},
{
"@type": "ListItem",
"position": 2,
"name": "Acides aminés, peptides et protéines",
"item": "https://questionsmedicales.fr/mesh/D000602"
},
{
"@type": "ListItem",
"position": 3,
"name": "Protéines",
"item": "https://questionsmedicales.fr/mesh/D011506"
},
{
"@type": "ListItem",
"position": 4,
"name": "Protéines du cytosquelette",
"item": "https://questionsmedicales.fr/mesh/D003598"
},
{
"@type": "ListItem",
"position": 5,
"name": "Protéines de filaments intermédiaires",
"item": "https://questionsmedicales.fr/mesh/D007381"
},
{
"@type": "ListItem",
"position": 6,
"name": "Protéine gliofibrillaire acide",
"item": "https://questionsmedicales.fr/mesh/D005904"
}
]
}
},
{
"@type": "MedicalWebPage",
"name": "Article complet : Protéine gliofibrillaire acide - Questions et réponses",
"headline": "Questions et réponses médicales fréquentes sur Protéine gliofibrillaire acide",
"description": "Une compilation de questions et réponses structurées, validées par des experts médicaux.",
"datePublished": "2026-08-26",
"inLanguage": "fr",
"hasPart": [
{
"@type": "MedicalWebPage",
"name": "Diagnostic",
"headline": "Diagnostic sur Protéine gliofibrillaire acide",
"description": "Comment la GFAP est-elle mesurée ?\nQuel rôle joue la GFAP dans le diagnostic ?\nLa GFAP est-elle spécifique à certaines maladies ?\nPeut-on détecter la GFAP dans le sang ?\nQuels tests sont utilisés pour la GFAP ?",
"url": "https://questionsmedicales.fr/mesh/D005904#section-diagnostic"
},
{
"@type": "MedicalWebPage",
"name": "Symptômes",
"headline": "Symptômes sur Protéine gliofibrillaire acide",
"description": "Quels symptômes sont associés à des niveaux élevés de GFAP ?\nLa GFAP est-elle liée à des symptômes spécifiques ?\nQuels troubles peuvent augmenter la GFAP ?\nLa GFAP est-elle un indicateur de gravité des symptômes ?\nPeut-on utiliser la GFAP pour prédire des symptômes ?",
"url": "https://questionsmedicales.fr/mesh/D005904#section-symptômes"
},
{
"@type": "MedicalWebPage",
"name": "Prévention",
"headline": "Prévention sur Protéine gliofibrillaire acide",
"description": "Peut-on prévenir l'augmentation de la GFAP ?\nY a-t-il des habitudes de vie pour réduire la GFAP ?\nLa gestion du stress influence-t-elle la GFAP ?\nLes activités physiques peuvent-elles réduire la GFAP ?\nY a-t-il des vaccinations pour prévenir des maladies liées à la GFAP ?",
"url": "https://questionsmedicales.fr/mesh/D005904#section-prévention"
},
{
"@type": "MedicalWebPage",
"name": "Traitements",
"headline": "Traitements sur Protéine gliofibrillaire acide",
"description": "Comment la GFAP influence-t-elle le traitement ?\nY a-t-il des traitements ciblant la GFAP ?\nLa GFAP peut-elle être utilisée pour évaluer l'efficacité du traitement ?\nQuels médicaments peuvent affecter la GFAP ?\nLa GFAP est-elle impliquée dans la recherche de nouveaux traitements ?",
"url": "https://questionsmedicales.fr/mesh/D005904#section-traitements"
},
{
"@type": "MedicalWebPage",
"name": "Complications",
"headline": "Complications sur Protéine gliofibrillaire acide",
"description": "Quelles complications peuvent survenir avec des niveaux élevés de GFAP ?\nLa GFAP est-elle liée à des complications à long terme ?\nDes complications psychologiques peuvent-elles être liées à la GFAP ?\nComment la GFAP influence-t-elle la récupération après un AVC ?\nLa GFAP peut-elle prédire des complications post-traumatiques ?",
"url": "https://questionsmedicales.fr/mesh/D005904#section-complications"
},
{
"@type": "MedicalWebPage",
"name": "Facteurs de risque",
"headline": "Facteurs de risque sur Protéine gliofibrillaire acide",
"description": "Quels sont les facteurs de risque pour des niveaux élevés de GFAP ?\nL'âge influence-t-il les niveaux de GFAP ?\nLes antécédents familiaux augmentent-ils le risque de GFAP élevée ?\nLe mode de vie influence-t-il les niveaux de GFAP ?\nLes infections peuvent-elles affecter la GFAP ?",
"url": "https://questionsmedicales.fr/mesh/D005904#section-facteurs de risque"
}
]
},
{
"@type": "FAQPage",
"mainEntity": [
{
"@type": "Question",
"name": "Comment la GFAP est-elle mesurée ?",
"position": 1,
"acceptedAnswer": {
"@type": "Answer",
"text": "La GFAP est mesurée par des tests sanguins ou des analyses du liquide céphalorachidien."
}
},
{
"@type": "Question",
"name": "Quel rôle joue la GFAP dans le diagnostic ?",
"position": 2,
"acceptedAnswer": {
"@type": "Answer",
"text": "La GFAP aide à diagnostiquer des maladies comme la sclérose en plaques et les traumatismes crâniens."
}
},
{
"@type": "Question",
"name": "La GFAP est-elle spécifique à certaines maladies ?",
"position": 3,
"acceptedAnswer": {
"@type": "Answer",
"text": "Oui, des niveaux élevés de GFAP sont associés à des maladies neurodégénératives et des lésions cérébrales."
}
},
{
"@type": "Question",
"name": "Peut-on détecter la GFAP dans le sang ?",
"position": 4,
"acceptedAnswer": {
"@type": "Answer",
"text": "Oui, la GFAP peut être détectée dans le sang, indiquant des lésions cérébrales."
}
},
{
"@type": "Question",
"name": "Quels tests sont utilisés pour la GFAP ?",
"position": 5,
"acceptedAnswer": {
"@type": "Answer",
"text": "Les tests ELISA et les dosages immunologiques sont couramment utilisés pour mesurer la GFAP."
}
},
{
"@type": "Question",
"name": "Quels symptômes sont associés à des niveaux élevés de GFAP ?",
"position": 6,
"acceptedAnswer": {
"@type": "Answer",
"text": "Des niveaux élevés de GFAP peuvent indiquer des symptômes neurologiques comme des maux de tête ou des troubles cognitifs."
}
},
{
"@type": "Question",
"name": "La GFAP est-elle liée à des symptômes spécifiques ?",
"position": 7,
"acceptedAnswer": {
"@type": "Answer",
"text": "Oui, des niveaux élevés peuvent être liés à des symptômes de lésions cérébrales ou d'inflammation."
}
},
{
"@type": "Question",
"name": "Quels troubles peuvent augmenter la GFAP ?",
"position": 8,
"acceptedAnswer": {
"@type": "Answer",
"text": "Des troubles comme les AVC, les traumatismes crâniens et les infections peuvent augmenter la GFAP."
}
},
{
"@type": "Question",
"name": "La GFAP est-elle un indicateur de gravité des symptômes ?",
"position": 9,
"acceptedAnswer": {
"@type": "Answer",
"text": "Oui, des niveaux plus élevés de GFAP peuvent indiquer une gravité accrue des symptômes neurologiques."
}
},
{
"@type": "Question",
"name": "Peut-on utiliser la GFAP pour prédire des symptômes ?",
"position": 10,
"acceptedAnswer": {
"@type": "Answer",
"text": "Des études montrent que la GFAP peut aider à prédire l'évolution des symptômes neurologiques."
}
},
{
"@type": "Question",
"name": "Peut-on prévenir l'augmentation de la GFAP ?",
"position": 11,
"acceptedAnswer": {
"@type": "Answer",
"text": "Prévenir les traumatismes crâniens et les AVC peut aider à réduire l'augmentation de la GFAP."
}
},
{
"@type": "Question",
"name": "Y a-t-il des habitudes de vie pour réduire la GFAP ?",
"position": 12,
"acceptedAnswer": {
"@type": "Answer",
"text": "Adopter un mode de vie sain, incluant une alimentation équilibrée et de l'exercice, peut aider."
}
},
{
"@type": "Question",
"name": "La gestion du stress influence-t-elle la GFAP ?",
"position": 13,
"acceptedAnswer": {
"@type": "Answer",
"text": "Oui, une gestion efficace du stress peut potentiellement réduire les niveaux de GFAP."
}
},
{
"@type": "Question",
"name": "Les activités physiques peuvent-elles réduire la GFAP ?",
"position": 14,
"acceptedAnswer": {
"@type": "Answer",
"text": "Oui, l'exercice régulier peut contribuer à la santé cérébrale et potentiellement réduire la GFAP."
}
},
{
"@type": "Question",
"name": "Y a-t-il des vaccinations pour prévenir des maladies liées à la GFAP ?",
"position": 15,
"acceptedAnswer": {
"@type": "Answer",
"text": "Certaines vaccinations peuvent prévenir des infections qui pourraient augmenter la GFAP, comme la méningite."
}
},
{
"@type": "Question",
"name": "Comment la GFAP influence-t-elle le traitement ?",
"position": 16,
"acceptedAnswer": {
"@type": "Answer",
"text": "La GFAP peut guider les traitements en indiquant la présence de lésions cérébrales nécessitant une intervention."
}
},
{
"@type": "Question",
"name": "Y a-t-il des traitements ciblant la GFAP ?",
"position": 17,
"acceptedAnswer": {
"@type": "Answer",
"text": "Actuellement, il n'existe pas de traitements spécifiques ciblant la GFAP, mais des thérapies symptomatiques sont disponibles."
}
},
{
"@type": "Question",
"name": "La GFAP peut-elle être utilisée pour évaluer l'efficacité du traitement ?",
"position": 18,
"acceptedAnswer": {
"@type": "Answer",
"text": "Oui, la réduction des niveaux de GFAP peut indiquer une réponse positive au traitement."
}
},
{
"@type": "Question",
"name": "Quels médicaments peuvent affecter la GFAP ?",
"position": 19,
"acceptedAnswer": {
"@type": "Answer",
"text": "Certains médicaments anti-inflammatoires et neuroprotecteurs peuvent influencer les niveaux de GFAP."
}
},
{
"@type": "Question",
"name": "La GFAP est-elle impliquée dans la recherche de nouveaux traitements ?",
"position": 20,
"acceptedAnswer": {
"@type": "Answer",
"text": "Oui, la GFAP est un sujet de recherche pour développer de nouveaux traitements pour les maladies neurologiques."
}
},
{
"@type": "Question",
"name": "Quelles complications peuvent survenir avec des niveaux élevés de GFAP ?",
"position": 21,
"acceptedAnswer": {
"@type": "Answer",
"text": "Des niveaux élevés de GFAP peuvent entraîner des complications neurologiques graves, comme des AVC."
}
},
{
"@type": "Question",
"name": "La GFAP est-elle liée à des complications à long terme ?",
"position": 22,
"acceptedAnswer": {
"@type": "Answer",
"text": "Oui, des niveaux chroniquement élevés de GFAP peuvent être associés à des troubles neurodégénératifs."
}
},
{
"@type": "Question",
"name": "Des complications psychologiques peuvent-elles être liées à la GFAP ?",
"position": 23,
"acceptedAnswer": {
"@type": "Answer",
"text": "Oui, des niveaux élevés de GFAP peuvent être associés à des troubles psychologiques comme l'anxiété."
}
},
{
"@type": "Question",
"name": "Comment la GFAP influence-t-elle la récupération après un AVC ?",
"position": 24,
"acceptedAnswer": {
"@type": "Answer",
"text": "Des niveaux élevés de GFAP peuvent indiquer une récupération plus difficile après un AVC."
}
},
{
"@type": "Question",
"name": "La GFAP peut-elle prédire des complications post-traumatiques ?",
"position": 25,
"acceptedAnswer": {
"@type": "Answer",
"text": "Oui, des niveaux élevés de GFAP peuvent prédire des complications après un traumatisme crânien."
}
},
{
"@type": "Question",
"name": "Quels sont les facteurs de risque pour des niveaux élevés de GFAP ?",
"position": 26,
"acceptedAnswer": {
"@type": "Answer",
"text": "Les traumatismes crâniens, les AVC et certaines maladies neurodégénératives sont des facteurs de risque."
}
},
{
"@type": "Question",
"name": "L'âge influence-t-il les niveaux de GFAP ?",
"position": 27,
"acceptedAnswer": {
"@type": "Answer",
"text": "Oui, l'âge avancé est un facteur de risque pour des niveaux plus élevés de GFAP."
}
},
{
"@type": "Question",
"name": "Les antécédents familiaux augmentent-ils le risque de GFAP élevée ?",
"position": 28,
"acceptedAnswer": {
"@type": "Answer",
"text": "Oui, des antécédents familiaux de maladies neurologiques peuvent augmenter le risque de GFAP élevée."
}
},
{
"@type": "Question",
"name": "Le mode de vie influence-t-il les niveaux de GFAP ?",
"position": 29,
"acceptedAnswer": {
"@type": "Answer",
"text": "Oui, un mode de vie sédentaire et une mauvaise alimentation peuvent augmenter les niveaux de GFAP."
}
},
{
"@type": "Question",
"name": "Les infections peuvent-elles affecter la GFAP ?",
"position": 30,
"acceptedAnswer": {
"@type": "Answer",
"text": "Oui, certaines infections, comme la méningite, peuvent entraîner une augmentation des niveaux de GFAP."
}
}
]
}
]
}
Department of Psychiatry and Neurochemistry, Institute of Neuroscience and Physiology, the Sahlgrenska Academy at the University of Gothenburg, 43141 Mölndal, Sweden.
Clinical Neurochemistry Laboratory, Sahlgrenska University Hospital, Mölndal 43180, Sweden.
Department of Neurodegenerative Disease, UCL Institute of Neurology, Queen Square, WC1N 3BG London, UK.
UK Dementia Research Institute at UCL, WC1N 3BG London,UK.
Hong Kong Center for Neurodegenerative Diseases, Clear Water Bay, Hong Kong, China.
Wisconsin Alzheimer's Disease Research Center, University of Wisconsin School of Medicine and Public Health, University of Wisconsin-Madison, Madison, 53792 WI, USA.
Publications dans "Protéine gliofibrillaire acide" :
Department of Neurology, the Second Affiliated Hospital of Guangzhou Medical University, 250# Changgang East Road, Guangzhou 510260 Guangdong Province, China; Institute of Neuroscience and the Second Affiliated Hospital of Guangzhou Medical University, Key Laboratory of Neurogenetics and Channelopathies of Guangdong Province and the Ministry of Education of China, Collaborative Innovation Center for Neurogenetics and Channelopathies, 250# Changgang East Road, Guangzhou 510260, Guangdong Province, China. Electronic address: youminglong@126.com.
Publications dans "Protéine gliofibrillaire acide" :
Department of Psychiatry and Neurochemistry, Institute of Neuroscience and Physiology, the Sahlgrenska Academy at the University of Gothenburg, 43141 Mölndal, Sweden.
Clinical Neurochemistry Laboratory, Sahlgrenska University Hospital, Mölndal 43180, Sweden.
Publications dans "Protéine gliofibrillaire acide" :
Department of Psychiatry and Neurochemistry, Institute of Neuroscience and Physiology, the Sahlgrenska Academy at the University of Gothenburg, 43141 Mölndal, Sweden.
Institute of Psychiatry, Psychology and Neuroscience Maurice Wohl Institute Clinical Neuroscience Institute, King's College London, SE5 9RT London,UK.
NIHR Biomedical Research Centre for Mental Health and Biomedical Research Unit for Dementia at South London and Maudsley NHS Foundation, SE5 8AF London, UK.
Centre for Age-Related Medicine, Stavanger University Hospital, 4011 Stavanger, Norway.
Publications dans "Protéine gliofibrillaire acide" :
Neurochemistry Laboratory, Department of Clinical Chemistry, Amsterdam University Medical Centers, Vrije Universiteit Amsterdam, Amsterdam Neuroscience, 1081 HV Amsterdam, The Netherlands.
Publications dans "Protéine gliofibrillaire acide" :
Department of Neurology, the Second Affiliated Hospital of Guangzhou Medical University, 250# Changgang East Road, Guangzhou 510260 Guangdong Province, China; Institute of Neuroscience and the Second Affiliated Hospital of Guangzhou Medical University, Key Laboratory of Neurogenetics and Channelopathies of Guangdong Province and the Ministry of Education of China, Collaborative Innovation Center for Neurogenetics and Channelopathies, 250# Changgang East Road, Guangzhou 510260, Guangdong Province, China.
Publications dans "Protéine gliofibrillaire acide" :
Department of Neurology, the Second Affiliated Hospital of Guangzhou Medical University, 250# Changgang East Road, Guangzhou 510260 Guangdong Province, China; Institute of Neuroscience and the Second Affiliated Hospital of Guangzhou Medical University, Key Laboratory of Neurogenetics and Channelopathies of Guangdong Province and the Ministry of Education of China, Collaborative Innovation Center for Neurogenetics and Channelopathies, 250# Changgang East Road, Guangzhou 510260, Guangdong Province, China.
Publications dans "Protéine gliofibrillaire acide" :
Department of Neurology, the Second Affiliated Hospital of Guangzhou Medical University, 250# Changgang East Road, Guangzhou 510260 Guangdong Province, China; Institute of Neuroscience and the Second Affiliated Hospital of Guangzhou Medical University, Key Laboratory of Neurogenetics and Channelopathies of Guangdong Province and the Ministry of Education of China, Collaborative Innovation Center for Neurogenetics and Channelopathies, 250# Changgang East Road, Guangzhou 510260, Guangdong Province, China.
Publications dans "Protéine gliofibrillaire acide" :
Department of Neurology, the Second Affiliated Hospital of Guangzhou Medical University, 250# Changgang East Road, Guangzhou 510260 Guangdong Province, China; Institute of Neuroscience and the Second Affiliated Hospital of Guangzhou Medical University, Key Laboratory of Neurogenetics and Channelopathies of Guangdong Province and the Ministry of Education of China, Collaborative Innovation Center for Neurogenetics and Channelopathies, 250# Changgang East Road, Guangzhou 510260, Guangdong Province, China.
Publications dans "Protéine gliofibrillaire acide" :
Department of Neurology, the Second Affiliated Hospital of Guangzhou Medical University, 250# Changgang East Road, Guangzhou 510260 Guangdong Province, China; Institute of Neuroscience and the Second Affiliated Hospital of Guangzhou Medical University, Key Laboratory of Neurogenetics and Channelopathies of Guangdong Province and the Ministry of Education of China, Collaborative Innovation Center for Neurogenetics and Channelopathies, 250# Changgang East Road, Guangzhou 510260, Guangdong Province, China.
Publications dans "Protéine gliofibrillaire acide" :
Autoimmune encephalitis due to glial fibrillar acidic protein (GFAP) astrocytopathy is a rare cause of subacute neuropsychiatric changes. In this case, a young patient presented with a viral prodrome ...
There is a tremendous need for identifying reliable blood-based biomarkers for Alzheimer's disease (AD) that are tied to the biological ATN (amyloid, tau and neurodegeneration) framework as well as cl...
One hundred forty-four elderly participants underwent 18F-AV45 positron emission tomography (PET) scan, structural magnetic resonance imaging (MRI) scan, and blood sample collection. The composite sta...
Among the three plasma markers, GFAP best discriminated participants stratified by clinical diagnosis and brain amyloid status. Age was strongly associated with NfL, followed by GFAP and ptau-181 at m...
Our findings indicate that GFAP is of potential clinical utility in screening amyloid pathology and predicting future cognitive decline. GFAP, NfL, and ptau-181 were moderately associated with each ot...
Serum levels of neurofilament light chain (NfL) and glial fibrillary acidic protein (GFAP) reflect the disease activity and disability in central nervous system (CNS) demyelinating diseases. However, ...
We collected serum and clinical data of 365 patients with CNS inflammatory diseases from 12 hospitals. The serum NfL and GFAP levels were measured in patients with iTM (n = 37) and sTM (n = 39) using ...
Mean NfL levels were not significantly different between iTM (50.29 pg/ml) and sTM (63.18 pg/ml) (p = 0.824). GFAP levels were significantly lower in iTM (112.34 pg/ml) than in sTM (3814.20 pg/ml) (p ...
NfL levels and disease duration correlated with EDSS scores in sTM, and GFAP levels could be a promising biomarker to differentiate iTM from sTM....
Autoimmune glial fibrillary acidic protein (GFAP) astrocytopathy is a rare autoimmune disease, which is characterized by the immune system attacking astrocytes in the central nervous system, resulting...
We describe 2 patients with glial fibrillary acidic protein (GFAP) autoimmunity secondary to aseptic viral meningitis or meningoencephalomyelitis....
This study involved a retrospective chart review....
Two female patients, 45 and 55 years of age, developed aseptic meningoencephalomyelitis or meningitis; in one patient, it was likely caused by herpes simplex virus 2. The patients were recovering from...
These 2 patients had GFAP autoimmunity secondary to viral meningoencephalomyelitis or meningitis. This suggests that GFAP astrocytopathy might not always be a primary disease entity; it may follow ano...
Reactive astrogliosis has been demonstrated to have a role in Parkinson's disease (PD); however, astrocyte-specific plasma glial fibrillary acidic protein (GFAP)'s correlation with PD progression rema...
A total of 184 patients with PD and 95 healthy controls (HCs) were included in this prospective cohort study and followed-up for 5 years. Plasma GFAP, amyloid-beta (Aβ), p-tau181, and neurofilament li...
Plasma GFAP levels were higher in patients with PD (mean [SD]: 69.80 [36.18], pg/mL) compared to HCs (mean [SD]: 57.89 [23.54], pg/mL). Higher levels of GFAP were observed in female and older PD patie...
Plasma GFAP might be a potential biomarker for monitoring and predicting disease progression in PD....
Stable patients with multiple sclerosis (MS) may discontinue treatment, but the risk of disease activity is unknown. Serum neurofilament light chain (sNfL) and serum glial fibrillary acidic protein (s...
This observational study included patients enrolled in the Comprehensive Longitudinal Investigation in MS at the Brigham and Women's Hospital who discontinued treatment after >2 years disease activity...
Seventy-eight patients (92% female) discontinued treatment at a median (interquartile range) age of 48.5 years (39.0-55.7) and disease duration of 12.3 years (7.5-18.8) and were followed up for 6.3 ye...
Stable patients who discontinue treatment may be risk stratified by sNfL and sGFAP levels measured before and after discontinuing treatment. Further studies are needed to validate findings and determi...
Brain radial enhancement pattern on magnetic resonance imaging (MRI) has been identified as typical lesions in autoimmune glial fibrillary acidic protein astrocytopathy (GFAP-A). However, the authors ...
Data was retrospectively obtained from June 2013 through April 2023, and five GFAP-IgG-negative patients with valid data were recruited. Clinical information was either obtained by the investigators o...
Altogether five GFAP-IgG-negative patients with "meningoencephalitis/encephalitis" manifestations and brain radial perivascular enhancement were confirmed. One patient had peripheral lymphoma. Four pa...
GFAP-A-like disorders with radial perivascular enhancement could be found in GFAP-IgG-negative patients with or without neoplasm, which could provide new insight into the differential diagnosis of GFA...
Neurological damage is the pathological substrate of permanent disability in various neurodegenerative disorders. Early detection of this damage, including its identification and quantification, is cr...
Elevated levels of glial fibrillary acidic protein (GFAP) in plasma reflect neuroinflammation and are linked to cognitive decline. Preclinical studies show that dietary change can attenuate astrocyte ...